BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 20399946)

  • 1. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
    Heinemann LA; Dinger JC; Assmann A; Minh TD
    Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptives and thrombotic disease: risk of venous thromboembolism.
    Helmerhorst FM; Bloemenkamp KW; Rosendaal FR; Vandenbroucke JP
    Thromb Haemost; 1997 Jul; 78(1):327-33. PubMed ID: 9198174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
    Contracept Rep; 1996 Apr; 7(1):3-6. PubMed ID: 12320047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR; Ory H
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The truth about oral contraceptives and venous thromboembolism.
    Shulman LP; Goldzieher JW
    J Reprod Med; 2003 Nov; 48(11 Suppl):930-8. PubMed ID: 14686030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptives and venous thromboembolism: consensus conference statement.
    Dialogues in Contraception Consensus Conference (1995: Chicago)
    Dialogues Contracept; 1996; ():1-8. PubMed ID: 12320455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral contraceptives and venous thromboembolism.
    Paul C
    N Z Med J; 1996 Nov; 109(1033):413-5. PubMed ID: 8941290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A perspective on the concept of "risk".
    Westhoff CL
    Dialogues Contracept; 1996; 5(1):8-9. PubMed ID: 12347723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
    Suissa S; Blais L; Spitzer WO; Cusson J; Lewis M; Heinemann L
    Contraception; 1997 Sep; 56(3):141-6. PubMed ID: 9347203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differential risk of oral contraceptives: the impact of full exposure history.
    Lewis MA; MacRae KD; Kühl-Habichl D; Bruppacher R; Heinemann LA; Spitzer WO
    Hum Reprod; 1999 Jun; 14(6):1493-9. PubMed ID: 10359554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
    Lewis MA; Heinemann LA; Spitzer WO; MacRae KD; Bruppacher R
    Contraception; 1997 Sep; 56(3):129-40. PubMed ID: 9347202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.